• Loading stock data…

Leronlimab 14-Week, NASH Clinical Trial Met Primary Endpoint (PDFF) and Secondary Endpoint (cT1) for Per Protocol Population in 350 mg Weekly Dose

[#item_full_content]

Print Friendly, PDF & Email
Spread the word